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Background: Between country investigations suggest variation in guideline-indicated treatment and 
outcomes for non ST-segment elevation myocardial infarction (NSTEMI). Yet, little is known about 
within country variation in NSTEMI care.  
Purpose: To investigate within country variation in provision of guideline-indicated treatments for 
NSTEMI. 
Methods: National cohort study (232 hospitals, 357,228 NSTEMI in England, 2003-13) using data 
from the Myocardial Ischaemia National Audit Project (MINAP). We used a four level hierarchical 
Poisson model adjusted for patient baseline characteristics to quantify variation amongst Clinical 
Commissioning Group, CCG (n= 211) in the provision of ESC guideline-indicated treatments 
according to their date of publication.   
Results: The proportion of NSTEMI who received all care opportunities for which they were eligible 
was low (13.5% (48,257)) and varied between CCGs (median 12.8%, IQR 0.7 to 18.1%) (Figure 1). 
The greatest variation was for provision of aldosterone antagonists (16.7%, 0.0 to 40.0%) and least for 
use of an ECG (96.7%, 92.5 to 98.7%). The highest rates of care were for acute aspirin (median 
92.8%, IQR 88.6 to 97.1%), as well as aspirin (90.1%, 85.1 to 93.3%) and statins (86.4%, 82.3 to 
91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, 
IQR 8.7 to 16.6%), dietary advice (32.4%, 23.9 to 41.7%) and the prescription of P2Y12 inhibitors 
(39.7%, 32.4 to 46.9%). After adjustment for case mix, nearly all (99.6%) of the remaining variation 
in provision of care was due to between hospitals differences (median 64.7%, IQR 57.4% to 70.0%; 
between hospital variance: 1.92, 95% confidence interval 1.51 to 2.44; ICC 0.996, 0.976 to 0.999). 
Conclusions: Despite international recommendation for the management of NSTEMI, there is 
evidence for wide within country variation in the use of guideline-indicated treatments for NSTEMI. 
Improved adherence to guidelines will help reduce premature cardiovascular death across Europe.  
 
 
